Halozyme Therapeutics (HALO) Tops Q2 EPS by 15c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.29 -2%
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.91, $0.15 better than the analyst estimate of $0.76. Revenue for the quarter came in at $231 million versus the consensus estimate of $208.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.65-$4.05, versus the consensus of $4.72. Halozyme Therapeutics sees FY2024 revenue of $0.93-1.01 billion, versus the consensus of $0.98 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ExxonMobil shares drop as crude oil prices tumble
- Snap finalizing settlement to avoid LA trial on addiction claim - Bloomberg
- Information Services Group (III) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
